

# Chordate Medical announces change of Certified Adviser to Vator Securities

Chordate Medical Holding AB (publ) hereby announces that the company has entered into an agreement with Vator Securities AB ("**Vator Securities**") regarding the service as a Certified Adviser. Vator Securities will be appointed Certified Adviser (CA) on December 29th, 2023.

**For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

**Attachments**

[Chordate Medical announces change of Certified Adviser to Vator Securities](#)